Search clinical trials for: Atevirdine mesylate

Total 1653 results

University Hospital, Bordeaux

Completed

Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib (STIM 2)

Chronic Myeloid Leukaemia

France
Tianjin Medical University Cancer Institute and...
Zhejiang Cancer Hospital; Fudan University; Liaoning Tumor Hospital & Institute; Gansu Cancer Hospital

Unknown

Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy

Soft Tissue Sarcoma, Adult, Stage II

China
Kerman University of Medical Sciences

Terminated

Population Pharmacokinetics of Imatinib in CML Patients in Iran

Chronic Myelogenous Leukemia

Iran, Islamic Republic of
Hospital Virgen de la Salud

Completed

Imatinib in KIT-negative Systemic Mastocytosis

Systemic Mastocytosis

Spain
Novartis

Completed

Effect of Food on Bioavailability of Modified Release Formulations of Imatinib

Healthy
Assistance Publique Hopitaux De Marseille

Unknown

Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index (GIGIST)

Gastrointestinal Stromal Tumor
Novartis Pharmaceuticals

Terminated

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH) (IMPRES Extn)

Pulmonary Arterial Hypertension

Spain, Germany, Belgium, Switzerland, United States, Netherlands, Austria, Canada, Korea, Republic of, Italy, Japan, United Kingdom, France
Novartis Pharmaceuticals

Terminated

Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Germany, Belgium, United Kingdom, United States, Lithuania, Italy, Australia
Novartis Pharmaceuticals

Completed

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

Gastrointestinal Stromal Tumors

United States, France, Italy
Renato Melaragno

Unknown

Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)

Chronic Myeloid Leukemia (CML) With Philadelphia Chromosome-positive (Ph+)

Brazil
Hadassah Medical Organization
Novartis

Withdrawn

Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.

Metastatic Solid Tumors.

Israel
University of Bologna
Novartis

Unknown

Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias

Myeloproliferative Disorders | Hypereosinophilic Syndrome | Chronic Eosinophilic Leukemia (CEL)

Italy
Fudan University

Unknown

Study of Apatinib as an Inhibitor of Tumor Angiogenesis

Tumor

China
Xiangya Hospital of Central South University
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

Gastrointestinal Stromal Tumors

China
Annick Desjardins
Novartis Pharmaceuticals

Completed

Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG

Glioblastoma | Gliosarcoma

United States
Xi'an Xintong Pharmaceutical Research Co.,Ltd.

Recruiting

Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study

Chronic Hepatitis b

China
National Cancer Institute (NCI)

Completed

Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma

Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Adult Synovial Sarcoma

United States
Inhibikase Therapeutics, Inc.

Recruiting

A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg

CML

United States
Australasian Gastro-Intestinal Trials Group
European Organisation for Research and Treatment of Cancer - EORTC; Scandinavian...

Active, not recruiting

A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) (ALT GIST)

Gastrointestinal Stromal Tumour

Singapore, Norway, Finland, Australia, Sweden, France, United Kingdom, Spain, Netherlands, Slovakia
Eisai Inc.

Completed

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Hong Kong, Taiwan, Korea, Republic of, Singapore, Thailand, Malaysia
Bukwang Pharmaceutical

Completed

A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment

Gastric Cancer

Korea, Republic of
Novartis Pharmaceuticals

Completed

Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis

Systemic Sclerosis, Scleroderma

United States, Germany, Italy, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)

Gastrointestinal Stromal Tumors

France, Italy, Germany, United States
David Miklos
Novartis

Completed

A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease

Graft vs Host Disease

United States
Fujian Cancer Hospital

Unknown

Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens (ASGARD)

Advanced Metastatic Gastric Cancer
Guilin Medical University, China
Wuzhou Red Cross Hospital; Guangxi Naxishan Hospital; National Hospital of Guangxi...

Unknown

Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Tianjin Medical University Cancer Institute and...

Unknown

A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy

Gastric Cancer

China
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Completed

Therapy of Early Chronic Phase CML With Gleevec

Leukemia, Myeloid, Chronic-Phase

United States
Asan Medical Center

Withdrawn

Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumors
Novartis Pharmaceuticals

Terminated

Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg (MACS0375)

Gastrointestinal Stromal Tumors

China, Argentina, Russian Federation, Thailand, Korea, Republic of, Brazil, Canada, Venezuela, Mexico
Daiichi Sankyo, Inc.

Completed

Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma

Sarcoma

United States, Canada
Weill Medical College of Cornell University

Completed

Treatment of Polycythemia Vera With Gleevec

Polycythemia Vera

United States
Nantes University Hospital

Completed

High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML)

AML

France
Point Therapeutics

Terminated

Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Carcinoma, Non-Small Cell Lung

United States
University of Cincinnati
Novartis

Withdrawn

A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Chronic Myeloid Leukemia, Blast Crisis

United States
Fujian Medical University Union Hospital

Not yet recruiting

Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST (PIRKER)

Gastrointestinal Stromal Tumor of Rectum

China
First Affiliated Hospital of Zhejiang University
Zhejiang Cancer Hospital; Second Affiliated Hospital, School of Medicine, Zhejiang... and other collaborators

Recruiting

Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors (ZJGIST-01)

Gastrointestinal Stromal Tumor | Progression-free Survival | Neoadjuvant

China
Asan Medical Center

Completed

Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT

Gastrointestinal Stromal Tumors

Korea, Republic of
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Carcinoma, Non-Small-Cell Lung

China
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia

Chronic Myelomonocytic Leukemia | Chronic Myelogenous Leukemia

United States
Novartis Pharmaceuticals

Completed

Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia

Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; Southwest Oncology...

Terminated

Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

United States, Canada, Puerto Rico
Seoul St. Mary's Hospital
Ministry of Health & Welfare, Korea

Unknown

Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib

Chronic Myeloid Leukemia | Imatinib | Complete Molecular Response

Korea, Republic of
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Exatecan Mesylate in Treating Patients With Advanced Solid Tumors and Kidney Dysfunction

Unspecified Adult Solid Tumor, Protocol Specific

United States
National Cancer Institute (NCI)

Completed

E7389 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Daiichi Sankyo, Inc.

Completed

Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Novartis Pharmaceuticals

Terminated

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

Chronic Myeloid Leukemia (CML) | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)

Russian Federation
PETHEMA Foundation

Completed

Glivec in Ph Positive Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Cromosome Philadelphia Positive

Spain
Bausch & Lomb Incorporated

Completed

Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients

Allergic Conjunctivitis

United States
Xijing Hospital

Recruiting

Exploring the Molecular Mechanism Based on KIT Mutation (EMMBKM)

GIST

China

Search clinical trials for: Atevirdine mesylate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations